HNC: Human Neural Circuits Electrophysiology During Cognition
ConditionPsychiatric Disorder
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient in clinical neuro inpatient units at Stanford Medical Center
Age >18 years old
Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)
Disqualifiers
Lifetime psychotic disorder
Pregnant or nursing females
Prior adverse ketamine response
Use of ketamine in past 7 days
Trial design
Design model
Single group
Treatments tested in this trial
Ketamine Hydrochloride
DrugKetamine is an FDA-approved dissociative anesthetic.
Treatment groups
120 Participants
are divided into 1 treatment groupGroup A: KetamineExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)
The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms.
Time frame
up to 1 weekSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov